1. DESolve TM : Investigational device, not available for sale in the US
Elixir Medical Corporation Biodegradable Polymer Program Motasim Sirhan, CEO Elixir Medical
DESolve TM : Investigational device, not available for sale in the US
DESyne ® and DESyne BD ® : CE mark approved, not available for sale in the US 1

2. Elixir Medical: Innovating Vascular Restoration
Developing drug-device therapies to improve the standard of care for vascular intervention
Bilingual organization fluent in the development of drugs and devices for vascular applications
Developed and patented proprietary drug, Novolimus, a metabolite of Sirolimus with high potency and known safety profile
Developed highly biocompatible, biodegradable polymeric materials designed to sustain excellent long term clinical outcomes
Industry’s most comprehensive portfolio of drug eluting coronary vascular therapies
DESolveTM fully bioresorbable scaffold: enrolled pivotal trial for CE Mark, approval anticipated in 2013
DESyne BD® biodegradable polymer DES: CE Mark approved, launching in 2013
DESyne® durable polymer DES: CE Mark approved, beginning commercialization
Leverage proprietary know-how and technologies for peripheral vascular therapies
Adapting our bioresorbable scaffolds to SFA, BTK and pediatric applications where the need for improved therapies is acute and bringing them into the clinic 2

3. Elixir’s unique drug: Novolimus, a metabolite of Sirolimus
Known safety and efficacy
Active metabolite of Sirolimus
Binds to FKBP12, forming immunosuppressive complex
mTOR inhibitor
Known safety profile
Patients treated with Sirolimus orally / via DES exposed to significant amount of Novolimus
Potent anti-proliferative
Sustained performance with low drug dose
Excellent clinical outcomes
Exclusive supply and manufacturing
Active Pharmaceutical Ingredient (API)
Developed and chemically synthesized by Elixir
Exclusive supply agreement with a GMP certified API manufacturer
cGMP API Drug Master File complete
Proprietary drug with issued US patent
Oral Sirolimus
Formula: C50H77NO13
MW: 900
Drug Concentration
Elixir DES & Scaffold
Novolimus Exposure
Time
Not to scale

4. DESolve Breakthrough bioresorbable scaffold DESyne BD DESyne
Elixir has the broadest DES product portfolio in the industry for the markets of today and tomorrow
DESolve Breakthrough bioresorbable scaffold
DESyne BD
Biodegradable polymer DES designed to reduce the duration of DAPT
DESyne
Workhorse DES with best-in-class safety, efficacy

5. DESolve TM: the next quantum leap in vascular repair therapy
DESolve utilizes Elixir’s advanced platform technologies …
Ultrathin (< 3 µm) biodegradable polymer matrix with no primer coating
Drug release provides sustained neointimal inhibition
Low Novolimus drug dose of 5 µg / mm
… and combines them with a scaffold that bioresorbs in about 1 year
PLLA-based polymer with excellent durability, flexibility, and biocompatibility
Excellent radial strength with low recoil
Ability to expand in physiological conditions
Proprietary fabrication and processing technology
Allows visualization with MSCT
Two issued US patents
DESolve Breakthrough bioresorbable scaffold
DESyne BD
Biodegradable polymer DES designed to reduce the duration of DAPT
DESyne
Workhorse DES
Investigational use device .Product not available for sale in the US

6. DESolveTM has several key differentiating performance characteristics
Scaffold bioresorbs in about 1 year and provides excellent low late lumen loss at 6 months
Self-correcting scaffold property designed to resolve malapposition
Substantial safety margin for fracture resistance
Wide range of sizes to accommodate a broad range of vessel sizes and lesion lengths
Achieving ease of use and performance characteristics comparable with metallic DES systems 1 2 3 4

7. DESolveTM has demonstrated success in the clinic
First-In-Man trial complete with excellent 6 month and 12 month results
16 patients across Belgium and New Zealand
Primary endpoint: in-stent late lumen loss at 6 months – 0.19mm late lumen loss
Principal investigators: Dr. Stefan Verheye and Dr. John Ormiston
DESolve Nx CE Mark pivotal trial undergoing follow-up
126 patients across 15 sites: Europe, New Zealand, and Brazil
Principal investigators: Dr. Alexandre Abizaid, Dr. Joachim Schofer, Dr. Stefan Verheye
Primary endpoint: in-stent late lumen loss at 6 months; other endpoints:
Clinical: MACE, stent thrombosis
QCA: In-segment late lumen loss, binary restenosis, and percent diameter stenosis
Subset of patients: QCA, IVUS, OCT at 6, 12 and 24 months; MSCT at 12 months
Data analysis ongoing – 6 month clinical and imaging data to be presented at Euro PCR 2013
CE Mark approval anticipated in 2013

8. DESolveTM FIM 6 month angiographic results
In-scaffold Analysis
n=14 (paired)
RVD (mm)
post-procedure
2.84 ± 0.23
at 6 months
2.78 ± 0.27
MLD (mm)
2.60 ± 0.19
2.41 ± 0.28
% Diameter Stenosis
post procedure
8.05 ± 7.90
12.63 ± 11.37
Acute Recoil (%)
6.4 ± 4.6
Late Lumen Loss (mm) at 6 months
0.19 ± 0.19
Binary Restenosis (%) at 6 months
0.0

9. DESolveTM FIM 12 month MSCT results
In-scaffold Analysis
12-month Follow-up
n=12
Reference Diameter (mm)
 2.9 ± 0.5
Minimal Lumen Diameter (mm)
 2.4 ± 0.4
Mean Diameter Stenosis (%)
 15.9 ± 10.0
Mean Lumen area (mm2)
6.7 ± 3.5
Minimum Lumen area (mm2)
5.1 ± 1.2
Reference area (mm2)
 7.5 ± 2.3
Mean area stenosis (%)
22.4 ± 14.2
MLD and % DS consistent between 6 and 12 months

10. post-stenting (baseline)
pre-stenting
69-yr old male
hyperlipidemia
hypertension
former smoker
stable angina
post-stenting (baseline)
6M FU
6 month follow-up
6M FU
12M FU
*Stefan Verheye, M.D., Ph.D.,
ZNA Middleheim Hospital, Antwerp, Belgium

11. CE Mark trial case presented live by Dr. A. Abizaid, Dr. D
CE Mark trial case presented live by Dr. A. Abizaid, Dr. D. Chamié at TCT 2012 demonstrates the conformability of the DESolveTM scaffold Severe lesion in proximal LAD with severe angulation (>90º)
Pre-placement
At placement
Post-placement
97o
DESolve
3,5 x 14mm
DESolve (92o)

12. DESyn BD ® : CE Mark-approved biodegradable polymer DES
Ultra-thin biodegradable polylactide-based polymer that dissolves within 6 months
No primer coating, allowing for a true BMS surface after biodegradation of polymer coating
Uniform drug distribution in vessel wall
DESolve Breakthrough bioresorbable vascular scaffold
DESyne BD
Biodegradable polymer DES designed to reduce duration of DAPT
Advanced Co-Cr stent platform
Thin stent struts with high flexibility and deliverability
Optimal vessel wall coverage for uniform drug delivery
Open cell design for ease of side branch access
DESyne
Workhorse DES
Unique drug agent Novolimus
Potent anti-proliferative with known safety profile
Achieves sustained clinical performance with low drug dose and low polymer load

13. DESyne BD ® 6 month angiographic and IVUS results
In-Stent Analysis
Novolimus
Zotarolimus
P value
RVD. mm
N(L)=119
N(L)= 38
Post-procedure
3.00±0.37
3.08±0.35
0.31
At 6-months
2.95±0.37
2.99±0.38
0.67
MLD / Late Lumen loss (LLL), (mm)
Acute gain
1.87±0.42
2.01±0.43
0.09
MLD post-procedure
2.76±0.37
2.90±0.34
0.04
MLD at 6-months
2.64±0.39
2.22±0.53
<0.001
LLL at 6-months (in-stent)
0.12±0.15
0.67±0.47
< 0.001
Diameter Stenosis (%)
8.5±44
6.2±4.5
0.002
11.0±6.6
25.6±15.1
Binary Restenosis (%) (in-stent)
0.0%
7.9%
0.003
%Neointimal volume obstruction (%)
3.6±4.2
20.7±14.2
< 0.001 

14. DESyne BD ® 12 month Clinical Results
0 to 360 days, % (n)
DESyne (N=112)*
Endeavor
(N= 31)
P-Value
HIERARCHICAL EVENTS
DEVICE-ORIENTATED COMPOSITE
2.7%
3.2%
1.00
CARDIAC DEATH
0.0% --
TARGET VESSEL MI
0.9%§
CLINICALLY-INDICATED TLR
1.8%
0.52
Definite/Probable Stent Thrombosis
§Two vessel intervention with peri-procedural enzyme rise and no further complications
*Modified Intention to Treat (patients who received a study stent)

15. CE Mark-approved workhorse DES
FORMULA coating technology
Thin polymer and drug matrix coating without the need for a primer coating
Lowest polymer load for improved biocompatibility
DESolve Breakthrough bioresorbable vascular scaffold
DESyne BD
Biodegradable polymer DES designed to reduce duration of DAPT
Advanced Co-Cr stent platform
Thin stent struts with high flexibility and deliverability
Optimal vessel wall coverage for uniform drug delivery
Open cell design for ease of side branch access
DESyne
Workhorse DES
Unique drug agent Novolimus
Potent anti-proliferative with known safety profile
Achieves sustained clinical performance with the lowest drug dose among DES on the market

16. DESyne ® EXCELLA II 9 month angiographic and IVUS results
In-Stent Analysis
Novolimus
Zotarolimus
P value
RVD (mm)
N(L)=154
N(L)= 75
Post-procedure
2.84±0.43
2.91±0.38
0.20
At 9-months
2.82±0.44
2.70±0.42
0.06
MLD / Late Lumen loss (LLL), (mm)
Acute gain
1.36±0.40
1.47±0.36
0.047
Acute gain (%)
46.48±11.65
47.51±11.13
0.53
MLD post-procedure
2.48±0.39
2.57±0.37
0.10
MLD at 9-months
2.36±0.48
1.95±0.48
< 0.001
LLL at 9-months
0.11±0.32
0.63±0.42
Diameter Stenosis (%)
12±5
11±5
0.34
16±12
28±14
Binary Restenosis (%)
1.4% (2/138)
7.6% (5/66)
0.037
Volumetric Analysis
N(L)=34
N(L)=15
%Neointimal volume obstruction (%)
4.5±5.1
20.9±11.3
<0.001

17. DESyne ® EXCELLA II trial long-term clinical safety data
0 to 1080 days, % (n)
DESyne (N=139)
Endeavor
(N= 71)
P-Value
HIERARCHICAL EVENTS
DEVICE ORIENTATED COMPOSITE
5.0%
12.7%
0.057
CARDIAC DEATH
0.0% --
TARGET VESSEL MI
2.2%
1.4%
1.00
        Q-WAVE MI
        NON-Q- WAVE MI
0.7%
CLINICALLY-INDICATED TLR
9.9%
0.008
CI-PCI
4.2%
CI-CABG
NON TARGET VESSEL REVASCULARIZATION#
7.2%
5.6%
0.77
Definite & Probable Stent Thrombosis
#Clinically and non-clinically indicated

18. DESyneTM and DESyne BDTM
DESyne ® and DESyne BD ® leveraging thin stent struts, low polymer load and low drug dose
DESyneTM and DESyne BDTM
CypherTM
XienceTM & PromusTM
ResoluteTM
BioMatrixTM
SynergyTM
Strut Thickness (µm)
Polymer Thickness (µm)
Drug Load and release kinetics (µg)
Data on File at Elixir Medical

19. Elixir is leveraging its proprietary know-how and technologies for peripheral vascular therapies Bioresorbable technologies can improve outcomes, expanding the global peripheral vascular device market
Superficial femoral artery
Long lesion lengths and complex biomechanics lead to
Suboptimal long term patency rates with POBA and metallic BMS/DES
DCB leaves behind no permanent implant, but with sub-optimal long term patency
Below the knee
CLI below the knee is a very severe condition with ~50% of cases resulting in death or amputation
Sub-optimal patency with POBA, DCB and BMS/DES
DESolve technology can overcome the limitations by offering the required radial support and leaving behind no permanent implant and potentially achieving optimal long term patency
Elixir activity
Entered pre-clinical testing in 2012, including pediatric indication
FIM studies in 2013
Elixir activity
Preclinical studies in 2013
Future DESolve application includes iliac, pudendal, renal, carotid and neural arteries…

20. Elixir technology in new clinical indications
Pediatric Applications
Congenital Heart Disease
Pulmonary Artery Stenosis
births
Coarctation of Aorta
1-10,000 births
Currently treated by surgery/PTI with stenting
Typically requires multiple re-intervention to re-expand stent/surgery to accommodate somatic growth
DESolve technology can overcome the limitations by offering the required radial support , scaffold growth with somatic growth, followed by bioresorption and there by no repeat intervention
Elixir activity
Entered pre-clinical testing in 2012